Skip to content
naulon
Not checkedNot checked for notices yet.

Crizotinib in treatment of lung cancer

Arpita Singh, Anubhuti Singh, Kislay Kishore and 2 more

Muller Journal of Medical Sciences and Research · 2017

doi:10.4103/mjmsr.mjmsr_62_16 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Lung cancer is one of the most common malignancies and is the leading cause of cancer-related mortality throughout the world. Despite advances in surgery and chemotherapy, survival is still poor. Crizotinib is an oral inhibitor of multiple kinases, including anaplastic lymphoma kinase (ALK), and is indicated in the treatment of patients with locally advanced or metastatic? non small cell lung carcinoma (NSCLC) harboring ALK mutation as a targeted therapy. This is short drug review of crizotinib in the treatment of advanced lung cancer.

Abstract licence: CC BY-NC-SA

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.